Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.




To accelerate the discovery journey in cancer research, Leica Biosystems has partnered with Cell IDx, a technology leader in multiplexed cellular immunodiagnostics, developing highly sensitive and specific reagents for research and clinical immunohistochemistry to meet the needs of precision medicine.

Cell IDx technology allows the automated detection of multiple markers on the BOND RX staining system. The technology uses primary antibodies from any species, employing a single antigen retrieval step that allows detection of three chromogen stains in 4.5 hours and four chromogen stains in 6 hours. The process is simple, fast, and fully automated on the BOND RX platform and Aperio Brightfield scanners.

“With tissue sample sizes decreasing, and scientific advancements expanding the number of actionable biomarkers, multiplexing is a technique increasingly utilized by researchers to explore complex biology,” said Colin White, PhD, Global Vice President of Advanced Staining & Imaging at Leica Biosystems. “We are very pleased to be able to offer investigators an automated version of Cell IDx’s UltraPlex innovative, multiplex immunochromogenic technology on the BOND RX, thereby supporting research excellence through workflow efficiency and stain consistency.”

Combining Cell IDx’s UltraPlex multiplex immunochromogenic technology with Leica Biosystems automated staining and high throughput imaging systems will allow researchers to detect three or more markers chromogenically on a single slide using a standard pathology workflow. “With this co-marketing launch, Cell IDx very much looks forward to working with Leica Biosystems to provide these technologies to researchers in pharma, biopharma and research. Furthermore, plans are in place to rapidly expand the available multiplex panels, and we plan to offer development of custom multiplex biomarker panels,” said David Schwartz, Chief Executive Officer at Cell IDx.

For research use only. Not for use in diagnostic procedures.
Other whole slide imaging and analysis options are available.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Visit for more information.

About Cell IDx

Cell IDx is a technology leader in multiplexed cellular immunodiagnostics, developing highly sensitive and specific reagents for research and clinical immunohistochemistry to meet the needs of precision medicine. Our UltraPlex platform barcoding technology has enabled the generation of UltraPlex chromogenic and fluorescent multiplex immunohistochemistry panels, providing simultaneous detection of multiple markers in tissue sections and allowing analysis of sub-populations of cells “in situ” in the context of tissue morphology. Multiplex staining is achieved in virtually the same time it takes to perform a single marker stain, enabling truly rapid tissue phenotyping on a large scale. Our vision is the widespread application of this technology to address both the present and future needs of the research and clinical markets in oncology, immuno-oncology and other disease states. We offer an ever-expanding range of multiplex staining panels as well as rapid development of custom panels, tissue staining, imaging and analysis services. Cell IDx is based in San Diego, CA. For more information, visit